25H1 公司实现海外案例数11.72 万例（+103.5%），案例数占比提升至51.9%，客单价为612 美元 （+9.8%）；实现海外收入0.72 亿美元（+123%），收入占比提升至44%。毛利率61.2%（+2.96pct）， 海外分部净利率-7.5%，同比大幅收窄44.5pct。海外亏损的大幅收窄主要受益于收入规模高速扩张、海 外生产基地建设的延期以及海外人员团队扩张的暂缓。 国内实现稳健增长，维持行业领先地位。 海外案例数及收入均实现高增，国际化扩张逻辑持续兑现。 25H1 公司实现国内案例数10.9 万例（+14%），实现收入0.9 亿美元（+0.7%），实现分部净利润0.17 亿美元（+52%），净利率19.2%（+6.5pct）。 国内业务净利率大幅改善主要系海外业务增加了对总部固定费用的分摊，同时各项费用控制得当。25 年7 月公司完成对舒雅齐的战略投资，通过其高性价比的产品与覆盖广泛的诊所渠道网络，加速推进下 沉市场渗透。 机构：华福证券 研究员：陈铁林/何展聪 事件：公司公布25H1 业绩，报告期内实现收入1.61 亿美元（+33%），归母净利润0.15 亿美元 （+363%），案例数 ...

Investment Rating - The report maintains an "Outperform" rating for the company, with a target price of HKD 103.5 per share, indicating a potential upside from the current price of HKD 69.10 [2][5][14]. Core Insights - The company's revenue and profit for the first half of 2025 exceeded market expectations, driven by stabilization in domestic operations and rapid growth in overseas markets [3][10]. - In 1H25, the company achieved revenue of USD 160 million, representing a 33.1% increase year-over-year, with domestic revenue at USD 89.68 million (+0.6%) and overseas revenue at USD 71.67 million (+123.1%) [3][10][11]. - The share of overseas revenue reached 44.4%, up 17.9 percentage points, highlighting its importance as a key revenue source [3][10]. - The number of clear-aligner cases completed in 1H25 was 226,000, a 47.7% increase, with domestic cases growing by 14.0% and overseas cases surging by 103.5% [11][12]. Financial Performance - The gross margin for 1H25 was stable at 62.4%, while adjusted net profit increased by 84.8% to USD 19.47 million, resulting in a net margin of 12.1% [4][13]. - The company plans to implement aggressive market strategies in the second half of 2025 to maintain market share and continue its overseas expansion [5][14]. - Revenue forecasts for 2025 and 2026 have been raised to USD 340 million and USD 420 million, respectively, reflecting stronger-than-expected overseas growth [5][14]. Valuation Metrics - The report projects adjusted net profits of USD 26.75 million for 2025 and USD 32.80 million for 2026, with corresponding P/E ratios of 85x and 70x [5][14]. - The company is positioned as a leader in the clear-aligner market in China, with its overseas growth trajectory being increasingly validated [5][14].

Investment Rating - The report indicates a positive outlook for the invisible orthodontics industry, projecting a compound annual growth rate (CAGR) of 13.9% from 2024 to 2030, with market size expected to grow from 145 billion to 316 billion yuan [16][17]. Core Insights - The invisible orthodontics market in China is characterized by a large patient population, with over 1 billion individuals suffering from malocclusion, and a significantly higher prevalence of complex cases (Class II/III) compared to Western countries [4][20]. - The industry is currently dominated by two major players, Angelalign and Invisalign, which have established a "dual oligopoly" market structure, leading to intense competition and innovation [6][35]. - The report highlights the increasing demand for invisible orthodontics driven by rising consumer awareness of aesthetics and comfort, as well as advancements in technology such as AI design and 3D printing [17][38]. Summary by Sections Industry Overview - Malocclusion is defined as a dental condition resulting from abnormal jaw relationships, affecting oral health and function, necessitating orthodontic treatment [3][7]. - The prevalence of malocclusion in China is notably high, with complex cases reaching 45-50%, significantly above the 20-40% range seen in Europe and America [4][20]. Market Size - The market size for invisible orthodontics in China is projected to increase from 100 billion yuan in 2019 to 145 billion yuan in 2024, and further to 316 billion yuan by 2030 [16][17]. - The demand for invisible orthodontics is expected to rise due to improved consumer aesthetics awareness and the effectiveness of invisible aligners compared to traditional methods [17]. Supply Chain Analysis - The supply chain consists of upstream suppliers of orthodontic materials, midstream service providers, and downstream dental institutions, with a notable trend towards digital integration and efficiency [5][26]. - The core material for invisible aligners has transitioned from imported monopolies to domestic production, stabilizing the market with key players like Angelalign and Invisalign [5][29]. Competitive Landscape - The competitive landscape is marked by a "dual oligopoly" led by Angelalign and Invisalign, with both companies leveraging continuous technological advancements and clinical data to maintain their market positions [6][35]. - The report notes that the introduction of centralized procurement in 2022 has led to significant price reductions, enhancing affordability and market penetration, especially in lower-tier cities [22][23]. Technological Advancements - Innovations in materials, such as the development of PETG and TPU for aligners, have improved treatment outcomes and patient comfort [29][38]. - The integration of AI and 3D printing technologies is expected to further enhance the precision and efficiency of orthodontic treatments, creating opportunities for new entrants in the market [38].

Summary of the Conference Call for Times Angel Company Overview - **Company**: Times Angel - **Industry**: Orthodontics and dental technology Key Points and Arguments Financial Performance - **Revenue Structure**: In the first half of the year, Times Angel reported revenue of $89.68 million from the Chinese market and $71.67 million from international markets [2][4] - **Case Growth**: The number of cases in the Chinese market grew by 14% to 109,000, while international cases surged by 103.5% to 117,000 [2] - **Operating Profit**: Operating profit in China increased by 52% to $17.19 million, while losses in international markets narrowed to $5.43 million [2][5] - **Cash Flow**: Operating cash flow increased by 194.4% to $17.54 million [2] Market Strategy - **Pricing Strategy**: The company expanded its case numbers in China through strategic price reductions, while international gross margins improved by 3 percentage points to 61.2% [2] - **Product Innovation**: New products launched include the A10 Angel Expander and the headgear-style muscle stimulator, along with digital tools like the i also platform and "Angel Xiao Zhi" [2][6] - **Supply Chain Investment**: Plans to increase investment in supply chain and infrastructure to strengthen sales, marketing, clinical support, and customer service [2][7] Future Projections - **Case Projections for 2025**: Expected total cases to reach between 490,000 and 500,000, with 250,000 in China and 240,000 to 250,000 internationally [3][10] - **Profitability Timeline**: The company aims for international operations to achieve monthly profitability by the first half of 2027 [3][11] Competitive Landscape - **Differentiation Strategy**: The company does not intend to engage in price wars but will focus on product and service differentiation [3][15] - **Response to Competition**: Plans to enhance clinical service teams and accelerate new customer onboarding in response to increasing competition [3][13] Challenges and Risks - **Increased Losses**: Anticipated significant expansion of international operating losses in the second half of the year due to delayed expenses, recruitment issues, and increased tariffs [3][17] - **Patent Litigation**: Facing patent lawsuits from Align Technology, which could impact operations, but the company is prepared with legal strategies [19] Market Dynamics - **Domestic Market Trends**: The domestic market has seen a decline in average prices, with a focus on maintaining market share through competitive pricing strategies [20] - **Collective Procurement Policies**: New collective procurement policies are being implemented, which may rationalize product prices and require the company to adapt [21] Strategic Partnerships - **Investment in Shuyaki**: The investment in Shuyaki aims to quickly penetrate emerging markets, leveraging complementary channels while maintaining independent operations [3][23] Global Supply Chain Development - **Supply Chain Resilience**: Building a more resilient global supply chain with production and design centers in key regions like Brazil and Southeast Asia [8][18] Macro Environment Impact - **Consumer Sentiment**: Global consumer willingness has decreased, affecting demand for non-essential medical services, including orthodontics [26] Additional Important Points - **Focus on Early Treatment**: Plans to enhance public awareness in early orthodontic treatment and strengthen professional service capabilities in lower-tier markets [2][7] - **Data Security and Compliance**: Emphasis on strengthening data security and compliance with international regulations [2][9]

Group 1 - The core issue is the continuous share reduction by the founder of Times Angel, Li Huamin, raising concerns about the company's future prospects [1] - Since its IPO, Li Huamin has reduced her shareholding from 14.26% to 6.37%, indicating a significant lack of confidence in the company's performance [1] - The company's market capitalization has plummeted approximately 88% from its peak of over 80 billion HKD to around 10 billion HKD [1] Group 2 - Times Angel has experienced a decline in net profit for three consecutive years, dropping from 286 million CNY in 2021 to only 10.02 million USD in 2024, indicating a systemic weakening of profitability [2] - The company's current price-to-earnings ratio stands at about 107 times, significantly higher than its competitor Align Technology's 34 times, suggesting that market expectations for future growth are not being met [2] - Despite substantial investments in overseas market expansion, Times Angel reported a loss of approximately 29.7 million USD in international markets for 2024, reflecting ongoing challenges in converting investments into profits [2] Group 3 - The global orthodontic industry is facing significant challenges, as evidenced by Align Technology's stock price drop of 30% due to poor Q2 performance and layoffs, indicating potential market saturation [2] - Times Angel's overseas revenue remains minimal, with high investment costs and long conversion cycles, posing risks amid intense international competition [2] - Industry experts suggest that without a rapid increase in sales to support its valuation, Times Angel may face escalating challenges in the near future [2]

相关企业：爱齐（上海）商贸有限公司、成都新桥口腔医院有限公司、正雅齿科科技（上海）有限公 司、西安市恒惠科技有限公司、北京美立刻医疗器械有限公司、可丽尔医疗科技（常州）有限公司、天 津正丽科技有限公司、广州瑞通生物科技有限公司等。 关键词：牙齿矫治器分类、隐形矫治器的分类、隐形矫治器行业发展历程、居民人均医疗保健支出、隐 形矫治器行业产业链、正畸案例数、隐形正畸案例数、正畸市场规模、隐形正畸市场规模、隐形矫治器 行业市场规模、隐形矫治器行业发展趋势 一、隐形矫治器行业概述 内容概况：隐形矫治技术作为现代正畸领域的重大突破，在传承传统牙颌畸形矫治理念的基础上实现了 革命性创新，通过采用安全透明的弹性高分子材料制成的隐形矫治器，完全摒弃了传统托槽和钢丝的束 缚，让牙齿矫正过程既高效又隐蔽，且不影响日常生活和社交。近年来，随着人们对口腔健康和美观需 求的日益增强，隐形矫治器凭借其舒适、美观、便捷的特点，逐渐成为牙齿矫正市场的重要选择。尤其 是年轻一代消费者，更倾向于选择兼具功能性和美观性的隐形矫治方案，推动行业市场规模不断扩大。 与此同时，技术进步和产业链的完善进一步降低了隐形矫治器的生产成本，使得更多消费者能够负 ...

Group 1: Financial Performance - The company expects to achieve a net profit of $13.4 to $14.8 million in H1 2025, representing a year-on-year growth of 538.1% to 604.8% [1] - The growth in net profit is primarily driven by a low base in H1 2024, continued growth in overseas markets, and lower investment and operating expenses due to delays in establishing overseas production facilities [1] - Revenue projections for 2025 to 2027 are estimated at $318 million, $374 million, and $445 million, with year-on-year growth rates of 18.1%, 17.8%, and 18.8% respectively [3] Group 2: Market Expansion and Strategy - The company has made a strategic investment in the invisible orthodontics brand Shuyaki, acquiring a 35% stake to deepen its presence in emerging markets [2] - The company is focusing on enhancing accessibility to orthodontic services in lower-tier cities and county markets through its investment in Shuyaki, which is recognized for its cost-effective products and digital services [2] - The company has established a highly specialized team in Europe, Asia-Pacific, and the Americas, accelerating its overseas business with a significant increase in international cases from 33,000 in 2023 to 140,700 in 2024, a growth of 326.4% [1] Group 3: Marketing and Brand Influence - The company is expanding its sales and clinical teams strategically based on the development characteristics of different city tiers and is employing diversified marketing strategies to enhance brand influence [3] - Collaborative marketing initiatives include a summer event with Hasbro's My Little Pony in Shanghai, aimed at promoting early orthodontic education and family interaction [3] - The company launched the "Angel KiD Star Plan" in partnership with Xiaohongshu to promote early orthodontic awareness through authoritative reports and expert collaboration [3]

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Views - The company is expected to achieve a net profit of $13.4 to $14.8 million in H1 2025, representing a year-on-year growth of 538.1% to 604.8% [1] - The growth in net profit is primarily driven by a low base in H1 2024, continued growth in overseas markets, and lower investment and operating expenses [2] - The company has made a strategic investment in the orthodontic brand Shuyaki, acquiring a 35% stake to deepen its presence in emerging markets and enhance the penetration of invisible orthodontics [3] Financial Performance - The company’s revenue is projected to grow from $208 million in 2023 to $318 million in 2025, with year-on-year growth rates of 14.3% in 2023, 29.0% in 2024, and 18.1% in 2025 [5] - The net profit is expected to increase from $8 million in 2023 to $13 million in 2025, with growth rates of -75.4% in 2023, 60.4% in 2024, and 4.4% in 2025 [5] - The earnings per share (EPS) is forecasted to be $0.07 in 2025, with a price-to-earnings (P/E) ratio of 98.3 [5] Market Expansion - The company has established a localized development strategy, with significant growth in international cases, increasing from 33,000 in 2023 to 140,700 in 2024, a year-on-year increase of 326.4% [2] - The company is expanding its production capabilities in Brazil and is set to build a new manufacturing facility in Wisconsin, USA, which will be one of the most advanced centers for invisible orthodontics globally [2] Marketing Strategies - The company is actively enhancing its brand influence through diverse marketing strategies tailored to different city tiers, including collaborations with popular brands like My Little Pony and initiatives like the Angel KiD Star Plan [4]

Group 1: Company Performance Outlook - The company expects its performance in 2025 to exceed that of the previous year, adjusting strategies based on market conditions [2] - In the first half of 2024, domestic revenue accounted for 41.22%, indicating significant growth potential in the Chinese market [2] - The company aims for substantial revenue growth from its acquisition of Korean Wolan in 2025, focusing on market expansion and brand building [2] Group 2: Product Pricing and Market Strategy - Product prices remain stable, with changes primarily due to sales structure and tiered pricing policies [2] - The company has a balanced distribution of sales across multiple regions, including Europe, North America, Asia, South America, and Australia, reducing reliance on any single market [2] - Most tariffs on products exported to the U.S. are borne by customers, mitigating operational risks for the company [2] Group 3: Innovations and Digital Solutions - The company is responding to the digitalization needs in orthodontics by offering comprehensive digital solutions, including 3D printing technology [4] - In 2025, the company will upgrade its milling machine series and launch a 49-minute rapid sintering furnace, alongside advancements in 3D printing products [6] - The introduction of 3D printed full dentures and precise implant solutions for edentulous patients marks a significant innovation in the company's offerings [8] Group 4: Overseas Market Development - The company emphasizes matching customer needs in overseas markets and enhancing brand presence through training and relationship building [7] - Following the acquisition of Korean Wolan, the company is exploring the feasibility of establishing production bases in Europe and Asia [10] - The company is actively investing in channel development and market penetration to seize opportunities in the growing dental implant sector [9]